Compare EEX & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | SGP |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | 821 | N/A |
| Industry | Advertising | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.6M | 932.9M |
| IPO Year | N/A | N/A |
| Metric | EEX | SGP |
|---|---|---|
| Price | $5.01 | $24.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.70 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 254.5K | 55.7K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | $236.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.32 | $20.15 |
| 52 Week High | $5.45 | $30.56 |
| Indicator | EEX | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 50.07 |
| Support Level | $4.81 | $20.95 |
| Resistance Level | $5.18 | $26.55 |
| Average True Range (ATR) | 0.24 | 1.49 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 86.23 | 62.24 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.